The Food and Drug Administration (FDA) has found the Johnson & Johnson COVID-19 vaccine to be safe and effective in a briefing document on Wednesday morning, lending support to its emergency use authorization.
The vaccine’s trial data results are “consistent with the recommendations set forth in FDA’s guidance Emergency Use Authorization for Vaccines to Prevent COVID-19,” wrote the FDA. They find that Johnson & Johnson “has provided adequate information to ensure the vaccine’s quality and consistency for authorization of the product” under emergency use authorization.
The vaccine was 66.9 percent effective at preventing moderate to severe infection in adults after 14 days and 66.1 percent effective in preventing the same after 28 days, the FDA says in a briefing document for the FDA’s Vaccines and Related Biological Products Advisory Committee. The FDA also finds that the vaccine has a “favorable safety profile” and relatively low mild or moderate side effects like headache and injection site pain.
The FDA also confirmed the company’s trial results that the vaccine was 100 percent effective at preventing hospitalization and death in their trials, a crucial benchmark for the vaccine. The FDA’s analysis was also slightly more optimistic than Johnson & Johnson’s original trial results. While the FDA found the same efficacy in the U.S. at preventing moderate to severe infection, 72 percent, they found a higher efficacy in South Africa than the trial results suggested, at 64 percent instead of 57 percent.
On Friday, the committee will meet to discuss the vaccine and vote on whether or not to recommend the vaccine for emergency use authorization. If they do vote to recommend the vaccine, then FDA approval could come as early as Saturday. This would make the Johnson & Johnson vaccine the third vaccine to be approved for use in the U.S., along with the two-shot Pfizer and Moderna vaccines.
Though the Johnson & Johnson vaccine’s trial results show that it is less effective than the two vaccines currently in use, health experts say that the results are still promising and that it could play a crucial role in helping to curb the virus. The first two vaccines approved for use had such a high efficacy rate that they set a higher bar than is necessary for an effective vaccine, said Anthony Fauci when the Johnson & Johnson results were originally released. Others have pointed out that the annual flu vaccine, for instance, is only 40 to 60 percent effective.
The Johnson & Johnson vaccine is also easier to store, ship and administer than the two vaccines currently in use, which will prove crucial as the U.S. rushes to vaccinate the population quickly. While it requires refrigeration for storage, it doesn’t require the ultra-low temperatures that the Pfizer and Moderna vaccines require. It’s also a single-shot regimen, as opposed to two, making it easier to manufacture and administer.
Since the Pfizer and Moderna vaccine rollouts began some months ago, there has been a growing body of evidence showing that the vaccines can prevent not only infection but also the spread of the virus — so, with at least two vaccines already cutting down on the spread of COVID-19 and a third likely to join them soon in helping to prevent hospitalization and death, there is hope yet in the face of a disease that has killed over half a million people in the U.S. so far.
However, there may still be supply issues with the Johnson & Johnson vaccine at first. The company had originally promised that it would have 12 million doses manufactured and ready to ship by the end of February, but on Tuesday, an executive for the company told lawmakers that it only had 4 million ready to ship by the time emergency authorization would come through. The White House confirmed on Wednesday that it was expecting 3 to 4 million doses by next week.
The company hopes to ramp up production by summer, however, and the executive said on Tuesday that Johnson & Johnson would have 20 million doses by the end of March and 100 million total doses available to deliver by the end of June.
The Biden administration also announced on Tuesday that it would be bumping up vaccine supplies to states with 14.5 million doses being shipped per week. White House Press Secretary Jen Psaki said that this was the fifth time the administration has increased distribution and is now at almost double the amount since Joe Biden took office.
Help us Prepare for Trump’s Day One
Trump is busy getting ready for Day One of his presidency – but so is Truthout.
Trump has made it no secret that he is planning a demolition-style attack on both specific communities and democracy as a whole, beginning on his first day in office. With over 25 executive orders and directives queued up for January 20, he’s promised to “launch the largest deportation program in American history,” roll back anti-discrimination protections for transgender students, and implement a “drill, drill, drill” approach to ramp up oil and gas extraction.
Organizations like Truthout are also being threatened by legislation like HR 9495, the “nonprofit killer bill” that would allow the Treasury Secretary to declare any nonprofit a “terrorist-supporting organization” and strip its tax-exempt status without due process. Progressive media like Truthout that has courageously focused on reporting on Israel’s genocide in Gaza are in the bill’s crosshairs.
As journalists, we have a responsibility to look at hard realities and communicate them to you. We hope that you, like us, can use this information to prepare for what’s to come.
And if you feel uncertain about what to do in the face of a second Trump administration, we invite you to be an indispensable part of Truthout’s preparations.
In addition to covering the widespread onslaught of draconian policy, we’re shoring up our resources for what might come next for progressive media: bad-faith lawsuits from far-right ghouls, legislation that seeks to strip us of our ability to receive tax-deductible donations, and further throttling of our reach on social media platforms owned by Trump’s sycophants.
We’re preparing right now for Trump’s Day One: building a brave coalition of movement media; reaching out to the activists, academics, and thinkers we trust to shine a light on the inner workings of authoritarianism; and planning to use journalism as a tool to equip movements to protect the people, lands, and principles most vulnerable to Trump’s destruction.
We urgently need your help to prepare. As you know, our December fundraiser is our most important of the year and will determine the scale of work we’ll be able to do in 2025. We’ve set two goals: to raise $130,000 in one-time donations and to add 1422 new monthly donors by midnight on December 31.
Today, we’re asking all of our readers to start a monthly donation or make a one-time donation – as a commitment to stand with us on day one of Trump’s presidency, and every day after that, as we produce journalism that combats authoritarianism, censorship, injustice, and misinformation. You’re an essential part of our future – please join the movement by making a tax-deductible donation today.
If you have the means to make a substantial gift, please dig deep during this critical time!
With gratitude and resolve,
Maya, Negin, Saima, and Ziggy